FOLH1 and prostate carcinoma: 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) is the current benchmark for PSMA imaging in prostate cancer for accurately detecting and staging the disease [6]; it detects small metastases or recurrences due to its strong binding affinity, quick intracellular accumulation, and fast clearance from non-target tissues [8].